One of our ongoing investigations is aimed at determining the potential signaling pathway between Beclin‐1 and Mfn2 in cardiac MAMs and the responses of these signaling components to endotoxemia. The gene discussed is MFN2; the disease is serum lipopolysaccharide activity.